Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Fate Therapeutics (FATE)

Fate Therapeutics (FATE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Fate Therapeutics Reports Positive Phase 1 Results for FT819 in Lupus Treatment with Favorable Safety Profile and Initiates Dose Expansion Quiver Quantitative, Inc. - Tue Dec 10, 1:22AM CST

Fate Therapeutics reports positive results from FT819 study in lupus, showing effective B-cell depletion and favorable safety outcomes.Quiver AI SummaryFate Therapeutics, Inc. announced promising results...

FATE : 1.6800 (+1.20%)
Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus GlobeNewswire - Mon Dec 9, 3:01PM CST

FATE : 1.6800 (+1.20%)
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Dec 3, 3:01PM CST

FATE : 1.6800 (+1.20%)
Fate Therapeutics Announces Leadership Transition as Bob Valamehr, Ph.D. MBA, to Succeed Scott Wolchko as President and CEO Effective January 1, 2025 Quiver Quantitative, Inc. - Fri Nov 29, 10:24PM CST

Bob Valamehr will become CEO of Fate Therapeutics on January 1, 2025, succeeding retiring Scott Wolchko.Quiver AI SummaryFate Therapeutics, a clinical-stage biopharmaceutical company focused on induced...

FATE : 1.6800 (+1.20%)
Fate Therapeutics Announces Leadership Transition GlobeNewswire - Fri Nov 29, 12:05PM CST

FATE : 1.6800 (+1.20%)
Fate Therapeutics to Present at Upcoming December Investor Conferences GlobeNewswire - Tue Nov 26, 3:01PM CST

FATE : 1.6800 (+1.20%)
FATE Presents Encourgaing Data From Lupus Study, Stock Gains
FATE Presents Encourgaing Data From Lupus Study, Stock Gains Zacks Investment Research - Tue Nov 19, 2:10PM CST

Fate Therapeutics, Inc. FATE presented encouraging initial clinical and translational data from the first patient treated in its early-stage study on experimental pipeline candidate  FT819.Data showed...

IMCR : 28.33 (-0.33%)
CSTL : 27.53 (+1.62%)
FATE : 1.6800 (+1.20%)
SPRO : 0.9551 (-4.30%)
Fate Therapeutics Reports Successful Clinical Remission in First Patient Treated with FT819 for Lupus Nephritis Quiver Quantitative, Inc. - Mon Nov 18, 5:20PM CST

A lupus nephritis patient achieved clinical remission after FT819 treatment, showing promising safety and immune reset outcomes. Quiver AI SummaryFate Therapeutics, Inc. announced promising results from...

FATE : 1.6800 (+1.20%)
Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence GlobeNewswire - Mon Nov 18, 7:05AM CST

FATE : 1.6800 (+1.20%)
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence GlobeNewswire - Mon Nov 18, 7:00AM CST

FATE : 1.6800 (+1.20%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot